Leading HIV researchers have come to believe that at least one person has found a way to naturally rid their body of the virus.

The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who could potentially benefit from the prevention medication

New study shows that HIV can remain in the fluid surrounding the brain even after a decade on antiretroviral treatment.

Organizers of the International AIDS Conference set to be co-hosted by San Francisco and Oakland next summer are seeking $2 million from the state.

The largest treatment-as-prevention study for gay and bisexual men confirms that people on antiretroviral therapy with undetectable viral load do not transmit HIV.

Gilead Sciences announced last week it will donate millions of free bottles of Truvada for PrEP to the Centers for Disease Control and Prevention, but many AIDS activists say it is not enough.

The Centers for Disease Control and Prevention holds patents on the use of Truvada for HIV prevention, according to advocates, who want Gilead Sciences to pay future and retroactive royalties to make PrEP more widely available.

The U.S. Food and Drug Administration this week approved Dovato, a two-drug combination pill that provides a complete once-daily antiretroviral regimen for people starting HIV treatment for the first time.

A bill to make it easier for people to access PrEP via their local pharmacy survived its first committee vote April 8 after California lawmakers amended it to restrict the supply of the HIV prevention medication to one month.

An Australian man said he acquired HIV while taking on-demand PrEP before and after sex, which could represent the latest in a handful of cases of failure of the prevention pill.

Around 80 percent of new HIV infections are attributable to people who either do not know their status or are not receiving treatment to suppress viral load, according to a new report from the Centers for Disease Control and Prevention.

PrEP was a major topic at the Conference on Retroviruses and Opportunistic Infections this month in Seattle. Researchers showed that a new version of tenofovir works as well as the Truvada pill and offered insights about how gay and bisexual men are using

Project Inform, one of the nation's longest-running HIV education and advocacy organizations, has terminated its staff and is likely to cease operations, the Bay Area Reporter has learned.

A London man with long-term undetectable HIV despite stopping antiretroviral treatment a year and a half ago could potentially be the second case of an HIV cure, according to a report at the Conference on Retroviruses and Opportunistic Infections.